Corcept Therapeutics Faces Securities Class Action After FDA Rejection, Patent Loss

Lawsuit alleges company concealed FDA warnings about insufficient data while touting pipeline readiness

Mar. 30, 2026 at 9:09pm by Ben Kaplan

Got story updates? Submit your updates here. ›

A minimalist studio still life photograph featuring a shattered glass vial, a cracked pill capsule, and a stack of legal documents, conceptually representing the abstract corporate strategy, legal battles, and regulatory challenges faced by the pharmaceutical industry.The legal and regulatory challenges facing pharmaceutical companies can shatter investor confidence and disrupt drug development pipelines.San Francisco Today

A securities class action lawsuit has been filed against Corcept Therapeutics, alleging the company's management concealed repeated FDA warnings about insufficient data while publicly touting the readiness of its drug pipeline. The lawsuit comes after the FDA rejected one of Corcept's drug applications and the company lost a federal court patent case.

Why it matters

This case highlights the importance of transparency between pharmaceutical companies and regulatory agencies, as well as the potential legal consequences for allegedly misleading investors about the status of a company's drug development efforts.

The details

The lawsuit, filed by law firm Hagens Berman, alleges that Corcept Therapeutics failed to disclose that the FDA had repeatedly warned the company about insufficient data for one of its drug candidates. Despite these warnings, Corcept allegedly continued to publicly tout the readiness of its pipeline. The lawsuit was filed after the FDA rejected Corcept's drug application and the company lost a federal court patent case.

  • The lawsuit was filed on March 30, 2026.
  • The deadline for investors to join the class action is April 21, 2026.

The players

Corcept Therapeutics

A pharmaceutical company that develops drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders.

Hagens Berman

A national shareholder rights litigation firm that filed the securities class action lawsuit against Corcept Therapeutics.

FDA

The U.S. Food and Drug Administration, the regulatory agency that rejected one of Corcept's drug applications and provided repeated warnings to the company about insufficient data.

Got photos? Submit your photos here. ›

What’s next

The judge will decide on the class certification by the April 21 deadline, after which the case will proceed to trial if the class is certified.

The takeaway

This lawsuit underscores the importance of pharmaceutical companies being transparent with investors about the status of their drug development pipelines, especially when facing regulatory hurdles. Failure to disclose material information can have serious legal consequences.